Kura Oncology Inc KURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
-
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
-
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
-
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Kura Oncology to Participate in Three Investor Conferences in September
Trading Information
- Previous Close Price
- $9.70
- Day Range
- $9.05–9.68
- 52-Week Range
- $7.36–13.90
- Bid/Ask
- $9.05 / $9.25
- Shares Outstanding
- 88.96M
- Market Cap
- $807.76M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 260
- Website
- https://www.kuraoncology.com
Valuation
|
Metric
|
KURA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 18.05 |
Price/Sales | 11.24 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KURA
|
|---|---|
Quick Ratio | 4.47 |
Current Ratio | 4.73 |
Interest Coverage | −224.01 |
Quick Ratio
KURA
Profitability
|
Metric
|
KURA
|
|---|---|
Return on Assets (Normalized) | −40.18% |
Return on Equity (Normalized) | −151.40% |
Return on Invested Capital (Normalized) | −143.38% |
Return on Assets
KURA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>Lnkm&$ | LOCK|#wv>! | $127B | |||
| Moderna Inc
MRNA
| LOCK|f@&CzM | LOCK|?F^ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Np!&#C | LOCK|dgJ#m | $81B | |||
| argenx SE ADR
ARGX
| LOCK|SsVS&hC | LOCK|P^< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^qKfrmM | LOCK|x$B | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|X%pp?&> | LOCK|dj?< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|s#@>%D<s | LOCK|yj#< | $27B | |||
| Incyte Corp
INCY
| LOCK|dpv#gC | LOCK|z@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<!^Wq@b | LOCK|bD | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|w%M!$JZ | LOCK|%W$ | $14B |
United States